Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24319483 | 0.92 | NCF1 (0.42) | NCF1CHRM5ADRA2CCACNA2D1CACNA1B | |
| SCHEMBL118241 | 0.90 | CHRM5 (0.41) | CHRM5ADRA2CCACNA2D1CACNA1BCACNB1 | |
| SCHEMBL13007656 | 0.85 | NCF1 (0.38) | NCF1ACHEHRH3SIGMAR1 | |
| SCHEMBL11916111 | 0.84 | CHRM5 (0.50) | CHRM5ADRA2CACHEMAPT | |
| SCHEMBL2629515 | 0.84 | CHRM5 (0.56) | CHRM5ADRA2CACHEHRH3MAPT | |
| SCHEMBL20314515 | 0.84 | CNR1 (0.39) | CHRM5ADRA2CCACNA2D1CACNA1BCACNB1 | |
| SCHEMBL11916113 | 0.84 | CHRM5 (0.43) | CHRM5ADRA2CACHEKDM2BKCNH2 | |
| SCHEMBL3436997 | 0.83 | NCF1 (0.52) | NCF1CHRM5ADRA2CCACNA2D1CACNA1B | |
| SCHEMBL21933470 | 0.83 | CHRM5 (0.36) | CHRM5ADRA2CACHEKDM2B | |
| SCHEMBL21934661 | 0.82 | CHRM5 (0.48) | CHRM5ADRA2CACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9604984-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9346815-B2 | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | NCF1 586/4885CHRM5 4768/4885ADRA2C 3298/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | NCF1 1922/4885CHRM5 4309/4885ADRA2C 4526/4885 |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | NCF1 1453/4885CHRM5 4710/4885ADRA2C 4346/4885 |
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | NCF1 1705/4885CHRM5 4743/4885ADRA2C 3842/4885 |
| US-20200129627-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | NCF1 586/4885CHRM5 4768/4885ADRA2C 3298/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | NCF1 3414/4885CHRM5 3171/4885ADRA2C 965/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | NCF1 3414/4885CHRM5 3171/4885ADRA2C 965/4885 |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | NCF1 586/4885CHRM5 4768/4885ADRA2C 3298/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | NCF1 1631/4885CHRM5 2851/4885ADRA2C 3132/4885 |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | NCF1 1333/4885CHRM5 4497/4885ADRA2C 4518/4885 |
| US-20150336962-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | NCF1 1705/4885CHRM5 4743/4885ADRA2C 3842/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | NCF1 586/4885CHRM5 4768/4885ADRA2C 3298/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | NCF1 1631/4885CHRM5 2851/4885ADRA2C 3132/4885 |
| US-20160237086-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | NCF1 1705/4885CHRM5 4743/4885ADRA2C 3842/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | NCF1 1333/4885CHRM5 4497/4885ADRA2C 4518/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | NCF1 1922/4885CHRM5 4309/4885ADRA2C 4526/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | NCF1 1705/4885CHRM5 4743/4885ADRA2C 3842/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | NCF1 586/4885CHRM5 4768/4885ADRA2C 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.